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For human embryonic stem cells (hESCs) to be used clinically, it is imperative that immune responses
evoked by hESCs and their derivates after transplantation should be prevented. Human leukocyte antigens
(HLA) and ABO blood group antigens are important histocompatibility factors in graft rejection. HLA
matching between recipient and unrelated donors, in particular, is important in improving outcomes in hema-
topoietic cell transplantation (HCT). We have established and successfully maintained 29 hESC lines and
analyzed the HLA and ABO genotypes of these lines. HLA-A, -B, -C and -DR (DRB1) genotyping was
performed by polymerase chain reaction (PCR) sequence-based typing and ABO genotyping was carried out
by PCR restriction fragment length polymorphism methods. To determine what proportion of the Korean
population would be covered by these cell lines in organ transplantation, 27 cell lines with HLA-A, -B, and
-DR data were evaluated for HCT (cord blood) donors and 28 cell lines with HLA-DR and ABO data were
evaluated for solid organ (kidney) transplantation donors, and then compared the data with those from 6,740
donated cord bloods. When 2 HLA mismatches are allowed for HCT, as currently accepted for cord blood
transplantation, it was estimated that about 16% and 25% of the possible recipients can find one or more
donor cell lines with ≤2 mismatches at A, B, DRB1 allele level and at A, B antigen/DRB1 allele level,
respectively. When HLA-DR antigen level matching and ABO compatibility was considered for solid organ
(kidney) transplantation, it was estimated that about 29% and 96% of the possible recipients can find one or
more ABO-compatible donor cell lines with 0 and 1 DR mismatches, respectively. We provided the first
report on the HLA and ABO genotypes of hESC lines, and estimated the degree of HLA and ABO matching
in organ transplantation for the Korean population.
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INTRODUCTION strated that the resulting cells are homogeneous and do
not form teratomas or cause cancer (40). Third, the im-
mune response/rejection caused by transplantation ofThe development of human embryonic stem cells
(hESCs), with their unlimited proliferation and differen- hESCs or their differentiated derivatives should be pre-
vented.tiation ability, raises hope in patients that scientists may
one day be able to cure currently untreatable illnesses. The culture conditions for the derivation and mainte-
nance of hESCs necessary for clinical applications, suchReaching that goal will require overcoming certain prob-
lems with hESCs. First, the derivation, maintenance, and as cell therapy, have been established very rapidly, espe-
cially given the relatively recent development of thedifferentiation of hESCs should be accomplished under
xeno-free culture condition using good manufacturing field. The first report of hESC derivation in 1998 (65)
described an immunosurgery procedure for the isolationpractice (GMP) systems (32,58,66). Second, guided dif-
ferentiation methods of hESCs into a given functional of inner cell mass (ICM) cells, the use of mouse embry-
onic fibroblast (MEF) cells as feeder cells, and fetal bo-cell type must be established, and it must be demon-
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vine serum (FBS)/leukemia inhibitory factor (LIF) as MHC class II genes are HLA-DP, -DQ, and -DR. The
proteins (antigens) encoded by HLA are expressedcomponents of the culture medium. Currently, basic fi-
broblast growth factor (bFGF) is the most important fac- uniquely on the surface of cells in the body, and are
used to distinguish self from non-self; thus, differencestor for maintaining pluripotency, and Knockout serum
replacement (SR) and various human feeder cells origi- in MHC proteins become a serious impediment for
transplantation of hESCs or their differentiated deriva-nating from fetal skin, fallopian tube, foreskin, uterine
endometrium, and other tissues have replaced FBS and tives. In fact, a number of reports have suggested that
the risks of severe graft-versus-host disease (GvHD),MEFs in hESC culture (1,2,17,27,29,43,54). To avoid
contamination of animal-derived components during the graft failure, and mortality increase in proportion to
HLA disparity in allogeneic hematopoietic cell trans-derivation procedure, mechanical isolation of ICM has
been introduced instead of immunosurgery (60). Re- plantation (HCT) using bone marrow or umbilical cord
blood (7,31,49,50,57). It is very difficult to find suitable,searchers have attempted to develop defined culture me-
dia to allow culture of hESCs without feeder cells or SR fully HLA-matched donors; nevertheless, it is important
to minimize HLA mismatching between donor and pa-(3,17,35,37,67,68,70–72). The generation of clinical-
grade hESC lines under GMP conditions was recently tient to maximize graft outcome. Another factor to be
considered for transplantation is ABO blood group anti-reported, although these cells were prepared using US
FDA-approved clinical-grade materials instead of a gens. ABO compatibility between the donor and recipi-
ent has long been considered an absolute requirementxeno-free method (10).
It has been expected that stem cells and their deri- for successful solid organ transplantation, although ABO
incompatibility is not an obstacle for successful HCT (9).vates could be used for cell therapy as they might re-
place damaged tissue or organ (44). Unlike other stem The ideal solution for avoiding or minimizing im-
mune response/rejection in allogeneic transplantation iscells, hESCs have demonstrated true pluripotency, with
the potential to differentiate into all three germ layer to use donor cells that are genetically identical to those
of the patient. One way to accomplish this is by deriva-lineage cells (4,20,45,52). Thus, differentiated cells from
hESCs could be used to replace virtually any damaged tion of hESCs from oocytes generated by somatic cell
nuclear transfer (SCNT); another is to reprogram a pa-tissue or organ. To accomplish their therapeutic goals,
transplanted cells must not be rejected by the patient’s tient’s somatic cells, creating induced pluripotent stem
cells (iPS) (25). There are currently no reports demon-immune system (56). Previous reports have shown that
undifferentiated hESCs expressed low levels of major strating successful establishment of hESCs through
SCNT, perhaps because of potential ethical concerns as-histocompatibility complex (MHC) class I proteins but
do not express MHC class II proteins (14,34). Moreover, sociated with this method. Since Takahashi and Yama-
naka (63) first reported the induction of pluripotent stemit was reported that, during differentiation in vitro and
in vivo, the expression levels of MHC class I proteins cells from somatic cells in mice, there have been several
reports describing the successful production of iPS inin hESCs increased but MHC class II proteins were not
expressed on differentiated hESCs (14). The presence mice and humans using defined factors (22,38,41,46–
48,69). At present, the procedure for reprogramming toof MHC antigens on hESCs might induce an immune
response; thus, hESCs injected in vivo across histocom- generate iPS cells mostly involves genetic modification
using viral transduction, making it difficult to apply thepatibility barriers would be at risk for rejection (6).
Studies have reported that hESCs or their derivatives iPS solution in a clinical context, although some re-
searcher have shown that iPS are able to be generatedhave low immunostimulatory potential and failed to
stimulate proliferation of alloreactive human T cell (34), without virus construction (23,59,73). The next option
is to establish a hESC bank that has a large number ofand have shown that undifferentiated hESCs formed ter-
atomas in immunocompetent mice after humanization hESC lines, which collectively match HLA and ABO
types in a majority of patients. In the last 10 years, moreby injection of human peripheral blood leukocytes (13).
In contrast, it was reported that hESCs transplanted into than 400 hESC lines have been established and studied
worldwide (International stem cell registry, Universityimmunocompetent mice were effectively recognized and
rejected by the adaptive murine immune system (62). of Massachusetts medical school; http://www.umass
med.edu/iscr/index.aspx) (16,18); therefore, the organi-The immunogenicity of hESCs and their differentiated
derivatives, especially in vivo, is still not well under- zation of a large bank of hESC is not impossible. In
2005, using HLA data from 10,000 cardiac organ donorsstood.
A number of genes for human leukocyte antigens and 6,577 patients awaiting kidney transplants in the
UK, Taylor et al. (64) estimated that approximately 150(HLA) are highly polymorphic and encode various
MHC class I and II proteins; the three major MHC class hESC lines would be needed to establish a therapeutic
hESC bank capable of providing an HLA match forI genes are HLA-A, -B, and -C, and the three major
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most potential patients. Nakajima et al. (42) also esti- MO) in DMEM/F12 or acid Tyrode’s solution (Sigma)
in DMEM/F12. The trophoectoderm (TE) was then re-mated that a bank containing 170 hESC lines could offer
at least one hESC line with a single mismatch at one moved by immunosurgery using an anti-human whole
serum antibody (Sigma H-8765) and guinea pig comple-HLA loci to 80% of patients in the Japanese population.
If parthenogenetic homozygous hESC lines could be es- ment (Sigma S-1639 or Calbiochem 234395, La Jolla,
CA), or by mechanical isolation through manual transfertablished, the number of hESC lines needed to establish
such a bank would be reduced from 170 to as few as 55 of ICM outgrowths after seeding intact blastocysts on
feeder cells. The STO cell line (ATCC CRL-1503, Man-under the same conditions.
To date, we have established 31 hESC lines under assas, VA) or mouse embryonic fibroblasts (mEFs) were
used as mouse feeder cells; human embryonic fibro-various conditions that comply with the derivation of
clinical-grade hESCs, and have successfully maintained blasts (hEFs) or human foreskin fibroblasts (hFSs) were
used as human feeder cells after mitotic inactivation by29 such lines in the CHA Stem Cell Institute, Korea.
We have analyzed the HLA-A, -B, -C, and -DR geno- mitomycin C (Sigma) treatment. hEFs and hFSs were
established from aborted human fetuses and human fore-types of these 29 hESC lines (CHA-hES 3–26, M1, and
R1–R4) by polymerase chain reaction (PCR) sequence- skin tissue after obtaining informed consent. After
spreading the ICM clump on feeder cells, ES cell-likebased typing, and performed ABO genotyping using
PCR restriction fragment length polymorphism method. colony was cultured and mechanically dissected into
small clumps every 5–6 days. ES cell colonies were cul-We successfully determined the ABO genotypes of all
hESC lines and obtained HLA-A, -B, -C, and -DR geno- tured in DMEM/F12 medium supplemented with 20%
Knockout SR, 0.1 mM β-mercaptoethanol, 1% nones-type results from 27 of the 29 lines; the exceptions were
two hESC lines that showed chromosomal triploidy/tet- sential amino acids, 100 U/ml penicillin, 100 µg/ml
streptomycin, and 4 ng/ml basic fibroblast growth factorraploidy, and HLA-A, -C, and -DR results were obtained
in one of these two cell lines. In this study, we compared (bFGF; all products from Gibco/Invitrogen, Grand Is-
land, NY) at 37°C in a humidified 5% CO2 incubator.the HLA and ABO genotypes of the CHA-hESC lines
as donors with those of 6,740 donated cord blood sam- hESCs were cyropreserved by transferring hESC
clumps stepwise into media containing incremental in-ples as recipients to determine what proportion of the
Korean population would be covered by these cell lines creases in SR and DMSO (final composition: 90% SR +
10% DMSO), loaded into 0.25 ml straws (IMV, L’Aiglefor cell/tissue transplantation. For a simulation of match-
ing these cell lines as possible organ donors, 27 cell cedex, France; 30–70 clumps/straw), and frozen using
a programmed cell freezer (CryoMagic, Mirae Biotech,lines with HLA-A, -B, and -DR data were evaluated for
HCT (cord blood) and 28 cell lines with HLA-DR and Korea) (30).
To confirm endogenous alkaline phosphatase activityABO data were evaluated for solid organ (kidney) trans-
plantation. Our results demonstrate that established and hESC-specific surface marker expression in estab-
lished hESCs, we stained hESC colonies with an FRV-hESC lines have a potential as HCT donors with ≤2
ABDR (A, B antigen/DRB1 allele level) mismatches alkaline, sodium nitrite, and naphthol AS-BI alkaline so-
lution mixture (Sigma) for 20 min at room temperatureand as ABO-compatible solid organ (kidney) donors
with 0 DR (antigen level) mismatch for 25% and 29% (RT), and performed immunocytochemistry using anti-
bodies against SSEA-4 and TRA 1-60 (Chemicon, Tem-of the Korean population, respectively.
ecula, CA) after fixing with 4% paraformaldehyde
MATERIALS AND METHODS (PFA). We also ascertained the Oct-4 gene expression
hESC Derivation, Maintenance, and Characterization status by reverse transcription-polymerase chain reaction
(RT-PCR) or immunocytochemistry using an anti-OCT-Frozen human embryos from pronucleus to blastocyst
stage were donated by couples undergoing infertility 4 antibody (Chemicon). The following primer sequences
were used for Oct-4: (forward) 5′-gga aag gct tcc ccc tcatreatment after obtaining informed consent and approval
by the Institutional Review Board (IRB) of CHA Gang- ggg aaa gg-3′, (reverse) 5′-aag aac atg tgt aag ctg cgg
ccc-3′ (460 bp). A fluorescein-labeled goat anti-mousenam Medical Center. All processes followed IRB guide-
lines prior to 2005 and then relevant laws enacted since IgG antibody (Molecular Probes, Eugene, OR) was used
as a secondary antibody and nuclei were stained with2005. After thawing, donated embryos were cultured in
sequential media to the blastocyst stage for 1–6 days: DAPI (Vector Laboratories, Burlingame, CA).
For the cytogenetic analysis of hESCs, they were in-P1/Blastocyst medium (Irvine Scientific Inc. Santa Ana,
CA) or G1.2/G2.2 medium (Vitrolife, Englewood, CO). cubated for 3 h in hESC culture medium containing 0.1
µg/ml colcemid (KaryoMax colcemid solution; Gibco-hESC lines were established by removing the zona pel-
lucida of blastocysts (except hatched blastocysts) by BRL). Thereafter, they were treated with a hypotonic
solution (1% sodium citrate buffer) for 30 min and thentreatment with 0.3% pronase (Sigma P-5147, St. Louis,
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fixed with methanol and acetic acid (3:1, v/v). Cells remaining CHA-hESC lines were established on mouse
feeder cells. Twenty-nine CHA-hESC lines have beenwere spread onto a glass slide and dried, and chromo-
somes were identified by G banding. For karyotyping of cryopreserved at various passages; all 24 hESC lines
that have been thawed were found to be viable, and aneach cell lines, more than 20 metaphase chromosomes
were counted by an expert. additional 5 hESC lines that have not yet been thawed
are available for the future use (Table 1).Each hESC line was characterized with respect to
short tandem repeat (STR) loci by DNA fingerprinting. All hESC lines showed endogenous alkaline phos-
phatase activity and were positive for SSEA-4, TRA 1-Genomic DNA was extracted and 15 STR loci
(D3S1358, TH01, D21S11, D18S51, Penta E, D5S818, 60, and Oct-4. A karyotypic analysis showed that 26
hESC lines were normal [CHA-hES 3, 4, 10, 11, 12, 14,D13S317, D7S820, D16S539, CSF1PO, Penta D, vWA,
D8S1179, TPOX, FGA) and the gender marker Amelo- 15, 17, 20, 24, R1, R4 for 46,XY; CHA-hES 6, 7, 8, 9,
13, 18, 21, 22, 23, 25, M1,R2,R3 for 46,XX; CHA-hESgenin were co-amplified using a PowerPlex 16 System
(Promega, San Luis Obispo, CA) and an ABI 3100 Ge- 5, 46,XY, inv(9)]; three hESC lines—CHA-hES 16
(71,XXY), 19 [47,XX, der(2),−4,+5,+mar], and 26 (trip-netic Analyzer (Applied Biosystems, Foster City, CA).
The differentiation capacity of each hESC line was loidy/tetraploidy)—had abnormal karyotypes (Table 1).
DNA fingerprinting results (Table 2) were in agreementconfirmed by injecting undifferentiated hESCs into a
testicle of an NOD/SCID male mouse as clumps (about with the gender and triploidy results of karyotypic anal-
yses, and demonstrated that each of the 29 hESC lines1 × 106 cells/150 µl PBS). After 14–20 weeks, teratomas
were excised, fixed in PFA, embedded in paraffin, sec- were distinct from one other. The differentiation poten-
tial of the 26 karyotypically normal hESC lines was de-tioned, and then analyzed histologically after staining.
termined by injecting hESCs into the testicle of an
HLA and ABO Genotyping NOD/SCID male mouse. Twenty-three hESC lines, such
as CHA-hES 3–15, 17, 18, 22, 23, 24, M1, and R1–R4,Donated cord blood data, which included HLA geno-
types and ABO blood group antigens, was provided by formed teratomas, and their teratomas showed that these
hESCs differentiated into various cell types composediCORD (Cord Blood Bank of CHA Bio & Diostech Co.,
Seoul, Korea) and compared with HLA and ABO geno- of three germ layers (http://csci.cha.ac.kr/CHA-hES
Clines). Teratoma formation by injection of CHA-hEStypes determined for CHA-hESC lines.
High resolution (allele level) HLA typing of hESC 20, 21, and 25 is currently under examination to confirm
their differentiation ability using various stains. Theand cord blood was performed by PCR sequence-based
typing using a Secore Sequencing Kit (Invitrogen, karyotypically abnormal hESC lines such as CHA-hES
16, 19, and 26 have not been tested for teratoma forma-WI), using a DNA Engine Tetrad Thermal Cycler (Bio-
Rad, Hercules, CA) and an Applied Biosystems 3130xl tion.
Previous reports showing that classical HLA typingGenetic Analyzer (Applied Biosystems, Foster City,
CA). HLA-A, -B, -C, and -DR genotypes were deter- by serological methods (serotyping) is inaccurate have
led to the development of the more precise gene se-mined for hESC, and HLA-A, -B, and -DR genotypes
were determined for donated cord blood. quencing method (genotyping). In this study, we per-
formed high-resolution HLA-A, -B, -C, and -DR typingABO genotyping was performed by PCR restriction
fragment length polymorphism using the restriction en- of our 29 hESC lines and obtained complete HLA typing
results from all but two (Table 3). We were unable tozymes, Kpnl and Alul, and a PTC-300 Thermal Cycler
(MJ Research, Waltham, MA). obtain data from CHA-hES 16 (all HLA loci) and CHA-
hES 26 (HLA-B locus), which failed PCR sequence-
RESULTS based typing (twice in each case). In case of CHA-hES
16, we got the results from PCR reaction and sequencingAs part of a research effort to develop hESCs for
clinical applications, we have established 31 hESC lines for HLA-A, -B, -C, and -DR, but failed to get the match-
ing results from DATA base. It was inferred that theunder various conditions, 29 of which have been main-
tained and characterized (Table 1 and refer to http://csci. computer program recognized input data as an error be-
cause CHA-hES 16 had three chromosome 6 and thecha.ac.kr/CHA-hESClines). CHA-hES 3–12 were estab-
lished after isolation of ICM by immunosurgery and sequencing results would be three for each HLA gene.
For CHA-hES 26, we failed PCR reaction for onlyCHA-hES 13–26, M1, and R1–R4 were established by
mechanical isolation of ICM with no use of anti-human HLA-B. Of the 27 CHA-hESC lines, none were homo-
zygous at all of the HLA-A, -B, and -DR loci. Only aserum and guinea pig complement, conditions that ap-
proach xeno-free (see Discussion). CHA-hES 9, 18, and few hESC lines were homozygous at a single HLA lo-
cus: one (high-resolution, 4 digits) or five (low-resolu20–26 were established on human feeder cells and the
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Table 1. Derivation Conditions and Characteristics of hESCs Established and Maintained at the CHA Stem Cell Institute, Korea
Feeder Immunocytochemistry
ICM
Cell Lines Date Isolation D M Karyotype AP Oct-4 SSEA-4 TRA 1-60 Teratoma Freezing
CHA-hES 3 2004-03-18 IS STO MEF 46,XY + + + + yes yes
CHA-hES 4 2004-09-27 IS STO MEF 46,XY + + + + yes yes
CHA-hES 5 2004-10-07 IS STO MEF 46,XY,inv(9) + + + + yes yes
CHA-hES 6 2004-10-15 IS STO MEF 46,XX + + + + yes yes
CHA-hES 7 2004-11-05 IS STO MEF 46,XX + + + + yes yes
CHA-hES 8 2004-12-01 IS STO MEF 46,XX + + + + yes yes
CHA-hES 9 2004-12-14 IS hEF FS, TS 46,XX + + + + yes yes
CHA-hES 10 2005-11-22 IS STO MEF 46,XY + + + + yes yes
CHA-hES 11 2005-12-15 IS STO MEF 46,XY + + + + yes yes
CHA-hES 12 2005-12-20 IS STO MEF 46,XY + + + + yes yes
CHA-hES 13 2007-08-24 MI MEF MEF 46,XX + + + + yes yes
CHA-hES 14 2007-08-25 MI MEF MEF 46,XY + + + + yes yes
CHA-hES 15 2007-09-07 MI MEF MEF 46,XY + + + + yes yes
CHA-hES 16 2007-09-07 MI MEF MEF 71,XXY + + + + not tested yes
CHA-hES 17 2007-09-07 MI MEF MEF 46,XY + + + + yes yes
CHA-hES 18 2007-09-15 MI FS FS, TS 46,XX + + + + yes yes
CHA-hES 19 2007-11-22 MI MEF MEF 47,XX,der(2), + + + + not tested yes
-4,+5,+mar
CHA-hES 20 2007-12-18 MI FS FS, TS 46,XY + + + + injected yes
CHA-hES 21 2008-01-09 MI FS FS, TS 46,XX + + + + injected yes
CHA-hES 22 2008-01-11 MI FS FS, TS 46,XX + + + + yes yes
CHA-hES 23 2008-04-02 MI FS FS, TS 46,XX + + + + yes yes
CHA-hES 24 2008-04-02 MI FS FS, TS 46,XY + + + + yes yes
CHA-hES 25 2008-04-10 MI FS FS, TS 46,XX + + + + injected yes
CHA-hES 26 2008-04-14 MI FS FS, TS triploidy/ + + not tested + not tested yes
tetraploidy
CHA-hES M1 2008-01-11 MI MEF MEF 46,XX + + + + yes yes
CHA-hES R1 2008-04-14 MI MEF MEF 46,XY + + + + yes yes
CHA-hES R2 2008-04-14 MI MEF MEF 46,XX + + + + yes yes
CHA-hES R3 2008-05-09 MI MEF MEF 46,XX + + + + yes yes
CHA-hES R4 2008-05-09 MI MEF MEF 46,XY + + + + yes yes
The date is when seeded an ICM or whole blastocyst on feeder cells. ICM isolation was immunosurgery (IS) or mechanical isolation (MI). Feeder
represents feeder cells used for derivation (D) or feeder cells for maintenance (M). FS, human foreskin fibroblasts, TS, human testicular stromal
cells, AP, alkaline phosphatase.
tion, 2 digits) were homozygous for HLA-A; two (low- level (high-resolution, 4 digits) as well as at A, B anti-
gen/DRB1 allele level. The assignment of serologicalresolution) were homozygous for HLA-C; and one
(high-resolution) was homozygous for HLA-DRB1. antigens for particular HLA alleles were carried out on
the basis of The HLA Dictionary 2008 (21). Table 4To determine what proportion of the Korean popula-
tion would be matched for these hESC lines in terms of shows that among 6,740 cord blood samples as possible
recipients of HCT, 14 (0.21%), 117 (1.74%), and 958organ transplantation, we compared HLA and ABO
types of the hESC lines as donors with those of 6,740 (14.21%) could find 0, 1, and 2 mismatches, respec-
tively, at A, B, and DRB1 allele level. When we consid-donated cord blood samples as recipients. The donated
cord blood data were provided by iCORD, one of the ered A, B antigen/DRB1 allele level of matching, these
figures were increased to 20 (0.30%), 164 (2.43%), andKorean private cord blood banks. For a simulation of
HCT (cord blood), 27 cell lines with HLA-A, -B, and 1,510 (22.4%), respectively. Thus, a total of 1,089
(16.16%) and 1,694 (25.13%) possible recipients could-DR data were evaluated and for a simulation of solid
organ (kidney) transplantation, 28 cell lines with HLA- find one or more donor cell lines with ≤2 mismatches at
A, B, DRB1 allele level and at A, B antigen/DRB1 al-DR and ABO data were evaluated as possible donors.










Table 2. DNA Fingerprinting Results From 29 CHA-hESC Lines
Locus CHA-3 CHA-4 CHA-5 CHA-6 CHA-7 CHA-8 CHA-9 CHA-10 CHA-11 CHA-12 CHA-13 CHA-14 CHA-15 CHA-16 CHA-17
D3S1358 15/16 15/16 16/18 15/16 16/16 16/16 15/15 15/15 16/18 15/15 15/17 15/17 15/17 15/17 15/15
TH01 9/10 6/9.3 6/9 9/9 6/9 9/9 9/9 7/8 9/9 6/7 7/10 9/9 9/10 7/9 6/9
D21S11 33/34 31/32.2 30/30 30/31 29/29 31/32 30/32.2 30/31.2 28/32.2 31/31 30/31.2 30/31 29/30 28/30 30/30
D18S51 13/16 14/15 15/18 14/17 15/16 14/14 13/14 16/17 13/16 12/14 13/16 14/17 13/13 19/21 15/19
Penrta E 18/19 10/14 5/16 5/20 11/15 5/20 11/11 11/15 15/16 12/20 11/17 15/16 18/18 11/14 5/12
D5S818 11/13 12/13 13/13 11/11 11/12 10/11 10/11 10/12 11/13 11/11 10/10 10/13 12/12 11/12/13 11/12
D13S317 8/13 8/13 8/8 8/8 9/12 8/10 8/11 8/8 8/8 8/8 10/13 9/11 11/11 9/10 8/12
D7S820 11/11 11/11 12/12 9/12 11/12 9/11 10/10 9/12 8/11 9/11 11/12 11/12 11/12 10/12 9/10
D16S539 11/14 9/11 11/13 9/10 9/13 9/13 9/11 9/9 9/12 9/10 9/9 11/12 11/11 9/11/12 10/11
CSF1PO 12/12 10/11 10/13 12/12 10/11 12/12 12/12 10/11 9/12 11/11 12/12 12/12 12/12 10/12 11/11
Penta D 8/9 10/13 9/9 11/11 9/9 9/13 9/10 12/13 11/12 11/11 8/13 9/9 9/11 8/9/12 10/11
vWA 14/18 16/17 14/16 14/17 14/18 14/18 17/18 16/19 14/17 17/19 16/17 16/17 14/15 14/16/19 14/17
D8S1179 15/15 10/14 10/15 12/17 11/15 11/17 13/13 12/14 10/15 12/17 11/12 12/14 10/11 15/16 13/14
TPOX 8/11 8/11 8/9 8/11 8/12 8/11 8/8 10/10 11/11 11/11 8/9 9/13 8/9 8/8 11/11
FGA 23/23 24/24 22/23 21/22 23/23 19/21 19/24 22/22 23/26 21/21 23/23.2 18/21 20/23 22/23 23/23
Amelogenin XY XY XY XX XX XX XX XY XY XY XX XY XY XY XY
Locus CHA-18 CHA-19 CHA-20 CHA-21 CHA-22 CHA-23 CHA-24 CHA-25 CHA-26 CHA-M1 CHA-R1 CHA-R2 CHA-R3 CHA-R4 FS*
D3S1358 14/17 15/17 14/15 16/16 16/16 16/17 15/17 15/15 15/17 15/18 16/18 16/16 15/17 15/17 15/16/18
TH01 6/9 7/8 6/9 6/6 9/9 6/10 8/9 6/7 6/9 7/7 9/9 8/9 7/7 6/9 6/7/9
D21S11 30/31.2 30/31.2 30/31 32.2/32.2 32.2/32.2 30/30 29/32.2 29/30 31.2/33.2 29/32.2 29/31.2 29/29 30/30 31/31.2 30/31.2
D18S51 14/14 13/15 15/16 13/13 13/13 14/14 20/20 15/20 14/17 14/17 14/15 13/15 13/15 14/16 13/14/22
Penrta E 5/16 11/15 16/17 11/15 11/19 5/11 17/18 14/22 12/14 11/14 8/17 18/18 11/12 11/15 12/15
D5S818 10/13 11/12 12/13 9/12 11/13 11/12 11/11 9/12 10/11 10/11 9/11 11/12 9/13 9/13 10/11/12
D13S317 8/12 9/11 8/11 8/12 9/12 8/11 11/12 11/11 8/11 12/13 11/12 9/9 8/12 8/9 8/9/10
D7S820 10/11 10/12 11/12 11/12 10/10 11/12 8/11 8/12 11/12 10/11 11/11 12/12 10/11 8/10 10/11/13
D16S539 9/10 10/12 9/9 9/11 9/10 10/10 10/13 11/11 9/13 9/10 9/13 10/12 9/11 9/12 9/11/12
CSF1PO 9/10 10/12 11/12 9/10 12/12 12/13 11/11 10/10 9/12 12/12 11/11 11/13 10/11 10/12 11/12
Penta D 9/12 9/14 12/12 9/9 11/13 9/10 8/9 9/11 8/10 9/9 9/13 9/13 11/11 8/9 9/12/13
vWA 17/17 16/18 14/17 14/17 17/17 19/21 14/18 14/19 16/16 14/20 16/17 16/18 14/18 17/18 14/17/18
D8S1179 14/15 13/15 12/16 13/14 13/13 15/17 13/15 10/12 10/13 10/16 13/14 10/13 11/15 11/14 10/12/13
TPOX 8/11 8/9 8/11 9/11 11/11 8/9 8/8 8/9 8/12 8/11 11/11 8/11 8/8 8/11 9/10/11
FGA 20/21 23/24 23/25 22/25 22/22 19/21 20/25 23/23 22/24 23/25 21/21 22/24 23/25 21/24 21/23
Amelogenin XX XX XY XX XX XX XY XX XX XX XY XX XX XY XY
Raw data were not shown.
*FS, human foreskin fibroblasts were derived from foreskin tissues of two different donors.
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Table 3. HLA and ABO Genotypes of 29 CHA-hESC Lines
HLA-Class I HLA-Class II
ABO
Cell Line HLA-A HLA-B HLA-Cw HLA-DR Genotype
CHA-hES 3 A* 2402, 3101 B* 1507, 4601 Cw* 0102, 03031 DRB1* 0403, 0803 O/O
CHA-hES 4 A* 0207, 1101 B* 1801, 4601 Cw* 0102, 1203 DRB1* 0405, 1104 O/O
CHA-hES 5 A* 2402, 3303 B* 07021, 4403 Cw* 0702, 1403 DRB1* 01011, 0701 A/O
CHA-hES 6 A* 0201, 0203 B* 3802, 4001 Cw* 0304, 0702 DRB1* 0901, 1101 B/B
CHA-hES 7 A* 0201, 1101 B* 1511, 5401 Cw* 0102, 03031 DRB1* 0405, 1202 O/O
CHA-hES 8 A* 1101, 2402 B* 1527, 4801 Cw* 04011, 08011 DRB1* 0406, 1405 B/O
CHA-hES 9 A* 0201, 1101 B* 1301, 4001 Cw* 0304, 0702 DRB1* 1202, 1405 O/O
CHA-hES 10 A* 1101, 3004 B* 1401, 5401 Cw* 0102, 0802 DRB1* 0404, 1405 A/O
CHA-hES 11 A* 0201, 3101 B* 1518, 5401 Cw* 0102, 0704 DRB1* 0401, 1405 A/O
CHA-hES 12 A* 0203, 3004 B* 1401, 3802 Cw* 0702, 0802 DRB1* 0802, 1101 A/A
CHA-hES 13 A* 2402, 3001 B* 07021, 1302 Cw* 0602, 0702 DRB1* 01011, 0405 B/B
CHA-hES 14 A* 1101, 3303 B* 4403, 5101 Cw* 1402, 1403 DRB1* 0901, 1302 B/O
CHA-hES 15 A* 3101, 3303 B* 4403, 4601 Cw* 0102, 1403 DRB1* 0403, 1302 A/O
CHA-hES 16 N/A N/A N/A N/A O/O
CHA-hES 17 A* 3303, 6801 B* 5101, 5801 Cw* 0302, 1502 DRB1* 1302, 1407 A/O
CHA-hES 18 A* 2402, 2603 B* 1501, 5502 Cw* 0102, 0303 DRB1* 0901, 1501 B/O
CHA-hES 19 A* 0203, 2402 B* 3802, 5101 Cw* 0702, 1402 DRB1* 0803, 1502 B/O
CHA-hES 20 A* 0201, 0207 B* 1501, 4601 Cw* 0103, 04011 DRB1* 0901, 14011 B/O
CHA-hES 21 A* 0101, 3303 B* 3701, 4403 Cw* 0602, 0701 DRB1* 0301, 0701 A/O
CHA-hES 22 A* 0206, 0206 B* 4001, 5502 Cw* 0102, 0702 DRB1* 1202, 1501 O/O
CHA-hES 23 A* 2402, 3303 B* 4403, 4601 Cw* 0103, 1403 DRB1* 0901, 1501 A/O
CHA-hES 24 A* 0206, 3004 B* 1401, 35011 Cw* 08011, 0802 DRB1* 0404, 12011 A/B
CHA-hES 25 A* 0101, 0206 B* 35011, 3701 Cw* 03031, 0602 DRB1* 0405, 1001 O/O
CHA-hES 26 A* 0201, 0206 N/A Cw* 0102, 0304 DRB1* 0405, 1405 A/B
CHA-hES M1 A* 1101, 3101 B* 1501, 4002 Cw* 0304, 04011 DRB1* 0406, 1407 A/O
CHA-hES R1 A* 0206, 2402 B* 07021, 5901 Cw* 0102, 0702 DRB1* 01011, 0405 O/O
CHA-hES R2 A* 0201, 3303 B* 27051, 5801 Cw* 0102, 0302 DRB1* 01011, 1302 B/O
CHA-hES R3 A* 0206, 0207 B* 4601, 5101 Cw* 0102, 1402 DRB1* 0803, 12011 A/A
CHA-hES R4 A* 0301, 2402 B* 07021, 27051 Cw* 0202, 0702 DRB1* 01011, 01011 B/O
N/A, not available.
1Ambiguities: B*0702, *0702/61; B*3501, *3501/42; B*2705, *2705/13; Cw*0303, *0303/20N; Cw*0401, *0401/09N;
Cw*0801, *0801/22; DRB1*0101, *0101/07; DRB1*1401, *1401/54; DRB1*1201, *1201/06/10/17.
A second type of histocompatibility antigens, the ered, a total of 3,013 (44.7%) and 6,668 (98.93%) possible
recipients could find 0 and 1 DR antigen mismatched do-ABO blood group antigens, is also important to be con-
sidered in matching donor and recipient, especially in nor cell lines, respectively. When ABO compatibility was
also considered, these figures were decreased to 1,957solid organ transplantation. Matching of ABO blood
type is not essential in HCT, although ABO incompati- (29.04%) and 6,456 (95.79%), respectively.
bility may cause hemolysis after transplantation (61).
DISCUSSIONTable 3 shows the results of our examination of the
ABO blood types of 29 CHA-hESC lines. Ten of these Since the first report of hESC establishment, more
than 400 hESC lines have been established worldwideCHA-hESC lines were type A (A/A or A/O), nine were
type B (B/B or B/O), eight were type O, and two were (International stem cell registry, University of Massa-
chusetts medical school; http://www.umassmed.edu/type AB. In consideration of solid organ (kidney) trans-
plantation (http://www.unos.org), we analyzed HLA-DR iscr/index.aspx) (16,18). There is also an effort on the
part of several stem cell registries to disseminate infor-(DRB1) antigen level matching and ABO compatibility
(O to A, B, O, and AB; A to A and AB; B to B and mation regarding various hESC lines; the emergence of
large banks of hESC lines would be a logical next stepAB; AB to AB) between 28 CHA-hESC lines as possible
donors and 6740 donated cord blood samples as possible that may not be long in coming. Based on HLA match-
ing using data from donors and patients for organ/cellrecipients (Table 5). When only HLA match was consid-
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Table 4. Results of HLA-A, -B, -DRB1 Matching Between 27 CHA-hESC Lines and 6,740 Donated
Cord Blood Samples for Simulation of Stem Cell Transplantation
A, B, and DRB1 Allele Level A, B Antigen and DRB1 Allele Level
Cell Line Full Match 1 Mismatch 2 Mismatch Full Match 1 Mismatch 2 Mismatch
CHA-hES 3 0 2 16 0 2 37
CHA-hES 4 0 0 3 0 0 8
CHA-hES 5 7 30 131 9 29 148
CHA-hES 6 0 0 11 0 2 50
CHA-hES 7 0 2 22 0 2 43
CHA-hES 8 0 0 14 0 5 80
CHA-hES 9 0 0 30 0 1 46
CHA-hES 10 0 2 15 0 2 18
CHA-hES 11 0 0 6 0 0 13
CHA-hES 12 0 0 2 0 0 11
CHA-hES 13 0 12 54 0 12 67
CHA-hES 14 1 11 155 2 12 170
CHA-hES 15 0 1 67 0 1 73
CHA-hES 17 0 0 39 0 0 42
CHA-hES 18 0 1 15 0 3 35
CHA-hES 19 1 2 26 1 4 79
CHA-hES 20 0 3 29 0 8 94
CHA-hES 21 0 6 24 0 6 27
CHA-hES 22 0 0 2 0 0 24
CHA-hES 23 0 3 69 0 3 75
CHA-hES 24 0 2 21 0 5 47
CHA-hES 25 0 5 29 0 10 44
CHA-hES M1 0 3 23 0 3 37
CHA-hES R1 0 10 79 0 21 164
CHA-hES R2 5 12 95 7 15 156
CHA-hES R3 0 6 40 1 13 138
CHA-hES R4 0 4 16 0 5 20
Total (%)* 14 (0.21) 117 (1.74) 958 (14.21) 20 (0.3) 164 (2.43) 1510 (22.40)
*Total number (%) of cord blood samples matched for 1 or more CHA-hESC lines.
transplantation, the number of hESC lines needed for a with HLA-DR and ABO data as possible donors and
6,740 donated cord bloods as possible recipients fortherapeutic hESC bank has been estimated at approxi-
mately 150 in the UK and 200 in Japan (42,64). How- solid organ (kidney) transplantation revealed that about
29% and 96% of the possible recipients could find ABOever, no reports have calculated the number of hESC
lines needed for a bank using the HLA type of hESC compatible donor cell lines with 0 and 1 HLA-DR anti-
gen mismatches, respectively.lines. In this study, we performed high-resolution HLA
genotyping of HLA-A, -B, -C, and -DR, obtaining com- Realizing this potential and applying hESC-based
cell therapy clinically requires that a number of techni-plete results from 27 of the 29 CHA-hESC lines typed.
An evaluation of the 27 cell lines with HLA-A, -B, and cal issues be surmounted. First, the derivation of clini-
cal-grade hESC lines must not involve exposure to ani--DR data as possible donors and 6,740 donated cord
bloods as possible recipients for HCT (cord blood) mal materials during the derivation/propagation process
so as to avoid the risk of infection or an immune reac-showed that about 16% and 25% of the possible recipi-
ents could find one or more donor cell lines with ≤2 tion to animal substances. Also, all processes from em-
bryo production to hESC establishment and differentia-mismatches at A, B, DRB1 allele level and at A, B anti-
gen/DRB1 allele level, respectively. We also analyzed tion should be performed according to a GMP system in
consideration of clinical use (33,58,66). As the hESCthe ABO genotypes of all 29 CHA-hESC lines and
found that 34.5% (10/29) were type A, 31.0% (9/29) derivation method and culture condition have been de-
veloped into xeno-free system, we have successfully es-were type B, 21.6% (8/29) were type O, and 6.9% (2/
29) were type AB. An evaluation of the 28 cell lines tablished and maintained 29 hESC lines in GMP-grade
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culture room under various conditions (Tables 1 and 2). hESCs that complies with regulations governing the use
of human cells and cellular-based products intended forThe modifications made to achieve these near-clinical-
grade hESCs include changing the hESC derivation/ tissue repair and replacement in the US. If these hESC
lines prove suitable for therapeutic use, the first step to-propagation method from immunosurgery to mechanical
isolation of ICMs, and switching from mouse feeder ward clinical application of hESCs would be largely
solved.cells to human feeder cells. We have also recently begun
using human serum instead of FBS for feeder cell cul- A second important aspect of hESC technology that
must be resolved is the immunogenicity of hESCs, anture, but have not yet had an opportunity to apply this
modification to the establishment of new hESC lines. issue that has not been well studied. At the core of the
immune system are the MHC genes, which encode pro-Xeno-free SR from Invitrogen has recently come into
the market as a next-generation substitute for SR, but its teins expressed on the surface of cells; in humans, the
genetic subset that encodes cell surface antigens are theability to support growth and maintain the characteristics
of hESCs has not yet been verified. Crook et al. (10) HLA genes. MHC class I molecules are found on most
cells of the body, where they present peptides from cyto-reported the generation of six clinical-grade hESC lines
using current GMP-compliant materials and procedures. solic proteins that are recognized by cytotoxic T cells.
MHC class II molecules are found only on a few cellAlthough the authors of this study did not use material
that originated from humans, they developed a model types, including macrophages, dendritic cells, and B
cells, and present peptides from exogenous proteins thatfor applying GMP to the production of clinical-grade
Table 5. Results of HLA-DRB1 Antigen Level and ABO Blood Group Matching
Between 28 CHA-hESC Lines and 6,740 Donated Cord Blood Samples for Simulation
of Solid Organ Transplantation
DRB1 DRB1 0 Mismatch/ DRB1 DRB1 1 Mismatch/
Cell Line 0 Mismatch ABO Compatible 1 Mismatch ABO Compatible
CHA-hES 3 250 (3.71) 250 (3.71) 2,885 (42.80) 2,885 (42.80)
CHA-hES 4 130 (1.93) 130 (1.93) 2,360 (35.01) 2,360 (35.01)
CHA-hES 5 61 (0.91) 23 (0.34) 1,418 (21.04) 597 (8.86)
CHA-hES 6 73 (1.08) 32 (0.47) 910 (13.50) 358 (5.31)
CHA-hES 7 199 (2.95) 199 (2.95) 2,464 (36.56) 2,464 (36.56)
CHA-hES 8 179 (2.66) 69 (1.02) 2,266 (33.62) 1,101 (16.34)
CHA-hES 9 91 (1.35) 91 (1.35) 594 (8.81) 594 (8.81)
CHA-hES 10 179 (2.66) 76 (1.13) 2,266 (33.62) 993 (14.73)
CHA-hES 11 179 (2.66) 76 (1.13) 2,266 (33.62) 993 (14.73)
CHA-hES 12 74 (1.10) 37 (0.55) 1,109 (16.45) 505 (7.49)
CHA-hES 13 185 (2.74) 70 (1.04) 2,911 (43.19) 1,153 (17.11)
CHA-hES 14 145 (2.15) 44 (0.65) 999 (14.82) 376 (5.58)
CHA-hES 15 260 (3.86) 123 (1.82) 2,449 (36.34) 1,090 (16.17)
CHA-hES 17 107 (1.59) 46 (0.68) 579 (8.59) 261 (3.87)
CHA-hES 18 134 (1.99) 62 (0.92) 751 (11.14) 286 (4.24)
CHA-hES 19 150 (2.23) 55 (0.82) 950 (14.09) 341 (5.06)
CHA-hES 20 95 (1.41) 40 (0.59) 816 (12.11) 335 (4.97)
CHA-hES 21 15 (0.22) 9 (0.13) 834 (12.37) 337 (5.00)
CHA-hES 22 108 (1.60) 108 (1.60) 529 (7.85) 529 (7.85)
CHA-hES 23 134 (1.99) 59 (0.86) 751 (11.14) 327 (4.85)
CHA-hES 24 199 (2.95) 20 (0.30) 2,464 (36.56) 283 (4.20)
CHA-hES 25 55 (0.82) 55 (0.82) 2,151 (31.91) 2,151 (31.91)
CHA-hES 26 179 (2.66) 18 (0.27) 2,285 (33.90) 255 (3.78)
CHA-hES M1 179 (2.66) 76 (1.13) 2,266 (33.62) 993 (14.73)
CHA-hES R1 185 (2.74) 185 (2.74) 2,911 (43.19) 2,911 (43.19)
CHA-hES R2 107 (1.59) 40 (0.59) 1,224 (18.16) 465 (6.90)
CHA-hES R3 105 (1.56) 47 (0.70) 1,213 (18.00) 560 (8.31)
CHA-hES R4 843 (12.51) 382 (5.67) 5,897 (87.49) 2,240 (33.23)
Total (%)* 3,013 (44.70) 1,957 (29.04) 6,668 (98.93) 6,456 (95.79)
*Total number (%) of cord blood samples matched for 1 or more CHA-hESC lines.
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are recognized by helper T cells. Previous reports have contrast to its prominent significance in solid organ
transplantation (19,26), it is still worth considering. Ourshown that undifferentiated hESCs weakly express
MHC class I antigens on the cell surface, but do not results indicate that the possibility of finding 0 HLA-DR
mismatches between our 28 CHA-hESC lines as possi-express MHC class II (14,34). When hESCs differentiate
into embryoid bodies (EBs) in vitro, their expression of ble donors and 6.740 donated cord bloods as possible
recipients for solid organ transplantation decreased fromMHC class I is increased, but MHC class II proteins
remain undetected (14). Treatment of undifferentiated 45% to 29% when ABO compatibility was taken into
account.hESCs with interferon-γ has also been shown to induce
the expression of MHC class I proteins, which are also Studies of HLA matching in unrelated donor HCT
using high-resolution matching have shown that match-increased in EBs by treatment with interferon-α, -β, or
-gamma (14). Drukker et al. (13) reported that hESCs ing all five HLA loci [HLA-A, -B, -C (class I) and
-DRB1, -DQB1 (Class II)] lowers the risks of clinicallyor their differentiated derivatives transplanted into hu-
man peripheral blood mononuclear cell-reconstituted severe GvHD, graft failure, and mortality, and further
showed that these risks are amplified with increasingmice were not rejected and developed normally into ter-
atomas. Cabrera et al. (8) suggested that the low expres- degree of locus mismatch (49). Although a perfect
match is clearly ideal, in reality it is very difficult tosion of MHC class I on hESCs was caused by down-
regulation of antigen-processing machinery (APM) find HLA full-matching unrelated donors. The current
standard for the selection of cord blood units includescomponents, similar to mechanisms in tumor cells, as
shown by the low or absent expression of APM compo- HLA-A, -B, and -DR typing, and the vast majority of
cord blood transplantations have been performed usingnents in the HS293 hESC line. Based on these data, it
has been suggested that hESCs and their derivatives units with match grades of 6/6, 5/6, or 4/6 at HLA-A, B
antigen level, and HLA-DR allele level (15,24,28,55). Ahave an immune-privileged status. A recent report has
reached an opposite conclusion, however, reporting that similar situation exists with respect to using hESCs and
their derivates for donor cell source for HCT: while ithESCs transplanted into immunocompetent mice were
effectively recognized and rejected by the adaptive mu- would be desirable to find HLA full-matching hESCs
for each patient, in practice it would require quite a largerine immune system (62). Using molecular imaging
techniques, this article showed that hESC survival after number of hESC lines. If two HLA-type mismatches are
assumed to be acceptable for transplantation of hESCs,transplantation was significantly limited in immunocom-
petent mice compared to immunodeficient mice, and re- as is the case for cord blood transplantation programs, it
was estimated that our 27 CHA-hESC lines can coverpeated transplantation of hESCs into immunocompetent
mice resulted in accelerated hESC death. about 16% and 25% of the Korean population with A,
B, DR allele level and A, B antigen/DR allele levelIf the immune character of hESCs is capable of elicit-
ing an immune response upon transplantation, the im- matches, respectively. None of our 27 CHA-hESC lines
was homozygous at all of the HLA-A, -B, and -DR loci,mune reaction caused by transplanted hESCs must be
solved before clinical application of hESCs. The strate- and very few were homozygous at an individual locus.
Ultimately, establishing hESC lines with homozygousgies for preventing hESC immune recognition are (i) es-
tablishment of large banks of immunophenotyped hESC HLA genotypes would be very helpful as this would re-
duce the number of hESC lines needed for a therapeuticlines to match MHC alleles between hESC lines and pa-
tients; (ii) generation of isogenic hES cell lines by so- hESC bank. In this context, hESC lines established from
human parthenogenetic blastocysts have been shown tomatic cell nuclear transfer using the patient’s own so-
matic cells or parthenogenesis of oocytes; (iii) induction possess homozygous HLA genotypes (36,53). Although
this latter strategy raises practical problems that wouldof tolerance by hematopoietic chimerism using hemato-
poietic cells differentiated from hESCs; (iv) creation of need to be resolved, this approach might prove to be a
practical way to create a full complement of HLA geno-universal cells by genetic modification to reduce the ex-
pression of MHC molecules; (v) transplantation of types using a minimal number of hESC lines.
When we analyzed HLA-DR antigen level matchinghESCs into immune-privileged sites, including the eye,
brain, or testis; and (vi) use of immunosuppressive med- and ABO compatibility between 28 CHA-hESC lines as
possible donors and 6,740 donated cord bloods as possi-ications (5,11,12,51).
Matching ABO blood group antigens is another fac- ble recipients for solid organ (kidney) transplantation
(Table 5), it was estimated that 28 CHA-hEC lines cantor that contributes to the success of transplantation (61).
Recently, Mölne et al. (39) reported that hESCs and dif- cover almost one third (29%) of the Korean population
with 0 DR mismatch and vast majority (96%) of theferentiated hepatocyte- and cardiomyocyte-like deriva-
tives expressed ABO blood group antigens. Although population with 1 DR mismatch.
In summary, we provide the first report on the HLAABO matching may seem less important than HLA type
matching in hematopoietic stem cell transplantation, in and ABO blood group genotypes of 28 CHA-hESC
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bryonic stem cell line HS293 is associated with the APMlines, and estimated the degree of HLA and ABO match-
components’ expression level. Cell Biol. Int. 31(9):1072–ing among these hESC lines as possible donors and
1078; 2007.
6,740 donated cord blood samples as possible recipients 9. Chen, Y. T.; Dejosez, M.; Zwaka, T. P.; Behringer, R. R.
for organ transplantation. As expected, only a small H1 and H9 human embryonic stem cell lines are heterozy-
gous for the ABO locus. Stem Cells Dev. 17(5):853–855;percentage (<0.5%) of possible recipients was fully
2008.matched with donor cell lines at the HLA-A, -B, and
10. Crook, J. M.; Peura, T. T.; Kravets, L.; Bosman, A. G.;-DR loci. However, if two HLA-type mismatches were
Buzzard, J. J.; Horne, R.; Hentze, H.; Dunn, N. R.; Zweig-
considered the minimum requirement for transplantation erdt, R.; Chua, F.; Upshall, A.; Colman, A. The generation
as currently accepted for umbilical cord blood transplan- of six clinical-grade human embryonic stem cell lines.
Cell Stem Cell 1(5):490–494; 2007.tation, it was estimated that our 27 CHA-hESC lines
11. Drukker, M. Recent advancements towards the derivationcan provide a coverage for 16% and 25% of the Korean
of immune-compatible patient-specific human embryonicpopulation with A, B, DR allele level and A, B antigen/
stem cell lines. Semin. Immunol. 20(2):123–129; 2008.
DR allele level matches, respectively. On the basis of 12. Drukker, M.; Benvenisty, N. The immunogenicity of hu-
these results, we estimate that approximately 190 (for A, man embryonic stem-derived cells. Trends Biotechnol.
22(3):136–141; 2004.B, DR allele level match) or 120 (for A, B antigen/DR
13. Drukker, M.; Katchman, H.; Katz, G.; Even-Tov Fried-allele level match) hESC lines would be needed to estab-
man, S.; Shezen, E.; Hornstein, E.; Mandelboim, O.;lish a therapeutic hESC bank for HCT to provide broad
Reisner, Y.; Benvenisty, N. Human embryonic stem cells
coverage for the Korean population. In addition, a stem and their differentiated derivatives are less susceptible to
cell bank derived from therapeutic cloning or repro- immune rejection than adult cells. Stem Cells 24(2):221–
229; 2006.gramming technologies would be required to provide pa-
14. Drukker, M.; Katz, G.; Urbach, A.; Schuldiner, M.;tient-specific stem cells and accommodate minor popu-
Markel, G.; Itskovitz-Eldor, J.; Reubinoff, B.; Mandel-lations.
boim, O.; Benvenisty, N. Characterization of the expres-
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